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ORIGINAL ARTICLE
Alcohol Consumption in Relation to Risk and
Severity of Chronic Widespread Pain: Results
From a UK Population-Based Study
GARY J. MACFARLANE AND MARCUS BEASLEY
Objective. To determine whether the reported level of alcohol consumption is associated with the likelihood of re-
porting chronic widespread pain (CWP) and, among persons with CWP, the associated disability.
Methods. In a population-based study in 2 areas of the UK, participants self-completed a postal questionnaire. They
were classified according to whether they met the American College of Rheumatology definition of CWP and whether
the pain was disabling (Chronic Pain Grade III or IV). They reported their usual level of alcohol consumption. Poten-
tial confounding factors on which information was available included age, sex, cigarette smoking, employment status,
self-reported weight and height, and level of deprivation.
Results. A total of 13,574 persons participated (mean age 55 years, 57% women) of whom 2,239 (16.5%) had CWP;
28% reported never regularly consuming alcohol, 28% reported consuming up to 5 units/week, 20% reported 6–10 units/
week, and 24% reported >10 units/week. Among persons with CWP, disability was strongly linked to level of alcohol
consumption. Prevalence of disability decreased with increasing alcohol consumption up to 35 units/week (odds ratio
[OR]21–35 units alcohol/week versus never drinkers 0.33 [95% confidence interval (95% CI) 0.19–0.58]) adjusted for confounders.
A similar relationship was found between reporting CWP and level of alcohol consumption (adjusted OR21–35 units alcohol/
week versus never drinkers 0.76 [95% CI 0.61–0.94]).
Conclusion. This study has demonstrated strong associations between level of alcohol consumption and both CWP and
related disabilities. However, the available evidence does not allow us to conclude that the association is causal. The
strength of the associations means that specific studies to examine this potential relationship are warranted.
INTRODUCTION
The etiology of chronic widespread pain (CWP) is complex.
Large-scale, cross-sectional population studies have pro-
vided insight into the characteristics of persons who report
CWP; they report high levels of psychological distress, poor
sleep quality and fatigue, and other somatic symptoms, and
they demonstrate specific attitudes, beliefs, and behaviors
about health (1). Fibromyalgia (the characteristic feature of
CWP) has been linked to adverse life events (2) and specifi-
cally to maltreatment in childhood (3). However, some of
these “associated” features may be consequences rather
than precedents of the onset of CWP (4), and there is evi-
dence that the relationship with potential etiologic factors,
such as adverse childhood factors, may partly be explained
by differential recall (5,6).
Cohort studies have allowed us to identify predictors of
CWP onset, such as psychological distress, poor sleep
quality, illness attitudes, and behavior (7,8). However,
since epidemiologic studies have demonstrated that the
first onset of CWP is uncommon in mid-adulthood, even
such longitudinal studies are likely to be examining pre-
dictors of episode onset, and lifestyle factors, experiences,
and attitudes may well have been affected by previous
experience of CWP. More generally, establishing the role
of lifestyle factors in the etiology of chronic diseases from
observational studies is challenging, and there are several
examples where erroneous conclusions have been drawn.
For example, while observational studies suggested that
higher levels of ß-carotene were associated with reduced
cardiovascular mortality, clinical trials of ß-carotene sup-
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plementation demonstrated an increased risk (9). The likely
reason for this was confounding factors, some unmeasured
and others measured with error (10).
In this context it was recently reported that among clinic
patients with fibromyalgia, moderate alcohol consumption
(in comparison to abstaining) was associated with reduced
symptom severity and increased quality of life (11). An
accompanying editorial posed the question, “Can alcohol
consumption be an alternative treatment for fibromyalgia?”
(12). If this were to be considered, then the observed rela-
tionship between alcohol consumption and fibromyalgia
severity and quality of life would need to be causal rather
than just an association, and the direction of causality
would need to be from alcohol consumption to symptom
severity rather than vice versa.
The purpose of the current analysis, using a previously con-
ducted epidemiologic study, was to determine whether we
could confirm, among persons with CWP, that moderate alco-
hol consumption was associated with lower disability and,
second, for the first time to examine whether usual level of
alcohol consumption was associated with likelihood of report-
ing CWP. Finally, for any association observed we wanted to
consider the likelihood that the association was causal.
MATERIALS AND METHODS
The MUSICIAN (Managing Unexplained Symptoms [chron-
ic widespread pain] In Primary Care: Involving Tradi-
tional and Accessible New Approaches) trial (see Appendix
A for investigators) is a randomized controlled trial investi-
gating the management of CWP. It tested the efficacy of
telephone-delivered cognitive–behavioral therapy and a
community-based exercise program in comparison to usual
care. Since identification of eligible patients was difficult
from primary care records, a large-scale recruitment survey
was undertaken, and it is data from this survey, the size of
which was determined by power calculations of the trial,
which are used in the current analysis. The study areas
were the city of Aberdeen, Scotland and North Cheshire,
England. The city of Aberdeen is an affluent city with high
employment, particularly in the fields of oil and higher edu-
cation. North Cheshire is a semirural area with market
towns, but from where residents also commute to major
industrial cities. The list of persons ages $25 years on par-
ticipating general practice registers was used as the sam-
pling frame for the recruitment survey. Since more than
95% of persons residing in the UK are registered with a gen-
eral practitioner, this represents a suitable population sam-
pling frame. A random sample of 45,949 persons on the
sampling frame was sent a questionnaire by post, and
nonresponders received a further questionnaire 2 weeks
later. The survey was started in April 2008, and mailings
were undertaken in 3 waves in order to accommodate treat-
ment within the trial. The survey finished in February 2009.
The study received ethics approval from the Cheshire Local
Ethics Committee, UK (reference 07/Q1506/61).
Pain. The questionnaire asked, “Thinking back over the
past month, have you had any aches or pains that have
lasted for one day or longer?” Respondents answering posi-
tively were invited to shade the location(s) of their pain on
4-view body manikins. From this we were able to identify
persons who reported pain satisfying the definition of CWP
used in the 1990 American College of Rheumatology (ACR)
criteria for fibromyalgia (13). Respondents also completed
the Chronic Pain Grade (CPG) scale, which measures impact
from grade I (low disability/low intensity) to IV (high dis-
ability, severely limiting), and was developed in the US, but
validated in the UK for use in postal questionnaires (14).
Alcohol consumption. Respondents were asked, “Have
you ever drunk alcohol regularly (at least once per week)
for a period of one month or longer?” If the response was
yes, respondents were asked, “How many units of alcohol
do you drink, on average, per week?” They were reminded
that 1 unit of alcohol is a half-pint of average strength beer/
lager or 1 small glass of wine or 1 single measure of spirits.
Confounding factors. Information was available on re-
spondent age, sex, employment status, usual number of ciga-
rettes smoked, and self-reported weight and height (allowing
calculation of body mass index [BMI]). Data on deprivation
were derived, based on a participant’s home address postal
code, using the Carstairs Index (15). This area-based index
uses measures of social class, car ownership, overcrowding,
and unemployment to estimate deprivation. Postal code
information was available for all participants in the North
Cheshire primary care network, but was only available from
those in the Aberdeen primary care network who consented
to be contacted for further studies.
Statistical analysis. The outcomes used in logistic reg-
ression analyses were 1) in the analysis among persons
reporting disabling CWP (severe chronic pain; CPG grades
III and IV) and 2) in the analysis involving all subjects, those
reporting CWP. The analysis was adjusted for the available
potential confounding variables listed above. Secondary
analyses were also done using those participants for whom
Carstairs Index scores were available, first an analysis
adjusted for the confounding factors in the main analysis,
and then repeated, additionally adjusting for the Carstairs
Index. The associations are reported as odds ratios (ORs)
with 95% confidence intervals (95% CIs).
Significance & Innovations
 Clinic patients with fibromyalgia who consume
moderate levels of alcohol have been shown, in a
single US study, to have lower levels of disability.
 We have replicated this result in a population-
based study of persons with chronic widespread
pain (CWP) in the UK.
 We have newly shown that the usual level of
alcohol consumption was associated with the
likelihood of whether a person reports CWP.
 Although we can’t say that the association is causal
at present, its magnitude makes a strong case for it
to be the specific focus of future studies.
1298 Macfarlane and Beasley
RESULTS
A total of 13,574 persons responded and provided useable
data for the current analysis. The mean age was 55 years
(interquartile range [IQR] 43–67 years), 57% were women,
and 16.5% (n52,239) satisfied the ACR definition of CWP
(prevalence: Aberdeen 16.5%, Cheshire 16.6%; P5 0.87).
With respect to alcohol consumption, 28% reported that
they had never regularly drunk alcohol, 28% reported up
to 5 units/week on average, 20% reported 6–10 units/
week, 15% reported 11–20 units/week, and 7% reported
21–35 units/week, while 2% reported that they drunk on
average .35 units/week. There were differences in alco-
hol consumption between the 2 study sites (P , 0.001): a
greater proportion of persons in Aberdeen reported never
having drunk regularly (Aberdeen 31.2% versus Cheshire
22.8%), while drinking .10 units/week was less common
in Aberdeen (21.2% versus 29.6%).
Carstairs Index of deprivation scores were available for
8,983 persons. Those with Carstairs Index scores were
younger than those without (median age 55 versus 56
years). Although significant (P , 0.5), the absolute differ-
ence was small. They were also significantly more likely to
be ex-smokers (30.8% versus 28.7%), to have drunk alcohol
regularly (74.5% versus 67.4%), and to report CWP (18.7%
versus 12.2%). There were no differences in sex, BMI, or
employment status, and there were no differences among
those with CWP in reported disability.
Is reported alcohol consumption related to disability
among persons with CWP? Among persons who reported
CWP, disabling pain (CPG III or IV) was strongly related to
reported alcohol consumption (Table 1). The proportion
of persons who never drunk regularly and who had dis-
abling pain was 47.2%, and this percentage decreased
with increasing reported alcohol consumption, such that
only 18.6% of persons with CWP who reported drinking
21–35 units/week had disabling pain, a difference that
remained highly statistically significant after adjustment
for confounders (adjusted OR 0.33 [95% CI 0.19–0.58]).
Among persons drinking at higher levels (.35 units/
week), the proportion with disabling pain was similar to
never regular drinkers (51.1%; adjusted OR 0.78 [95% CI
0.37–1.68]). There was no statistically significant differ-
ence in the relationship between alcohol consumption
and CWP disability in men and women, as assessed by an
interaction term in the logistic regression model; however,
the lowest disability occurred at 11–20 units/week in
women (17.5% versus 47.6% among never drinkers:
adjusted OR 0.35 [95% CI 0.21–0.60]) in comparison to
21–35 units/week in men (15.5% versus 45.5% among
never drinkers: adjusted OR 0.27 [95% CI 0.12–0.61]).
Similar patterns for the relationship between alcohol con-
sumption and disability were observed among the group
for whom Carstairs Index scores were available (Table 2).
After adjustment for deprivation, the OR for reporting dis-
abling pain in those drinking 21–35 units/week compared
Table 1. The relationship between reported alcohol consumption and pain disability among persons with CWP*
Reported units of
alcohol per week, no.
CPG I/II CPG III/IV
Crude
OR (95% CI)
Adjusted
OR (95% CI)No. % No. %
Never drunk regularly 352 52.9 314 47.2 1.00 1.00
0–5 396 67.1 194 32.9 0.55 (0.44–0.69) 0.65 (0.50–0.84)
6–10 282 75.4 92 24.6 0.37 (0.28–0.48) 0.49 (0.36–0.67)
11–20 216 82.1 47 17.9 0.24 (0.17–0.35) 0.36 (0.24–0.54)
21–35 96 81.4 22 18.6 0.26 (0.16–0.42) 0.33 (0.19–0.58)
.35 23 48.9 24 51.1 1.17 (0.65–2.11) 0.78 (0.37–1.68)
Total 1,365 66.3 693 33.7
* CWP5 chronic widespread pain; CPG5Chronic Pain Grade; OR5 odds ratio; 95% CI595% confidence interval.
Table 2. The relationship between reported alcohol consumption and pain disability among persons with CWP with Carstairs
Index scores available*
Reported units of
alcohol per
week, no.
CPG I/II CPG III/IV
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Adjusted for
deprivation
OR (95% CI)No. % No. %
Never drunk regularly 248 51.9 230 48.1 1.00 1.00 1.00
0–5 311 67.3 151 32.7 0.52 (0.40–0.68) 0.60 (0.45–0.81) 0.64 (0.47–0.89)
6–10 225 76.3 70 23.7 0.34 (0.24–0.46) 0.45 (0.31–0.64) 0.47 (0.33–0.67)
11–20 164 82.8 34 17.2 0.22 (0.15–0.38) 0.31 (0.20–0.50) 0.34 (0.21–0.55)
21–35 77 81.1 18 19.0 0.25 (0.15–0.43) 0.28 (0.15–0.52) 0.30 (0.16–0.57)
.35 18 48.7 19 51.4 1.14 (0.58–2.22) 0.66 (0.28–1.56) 0.66 (0.28–1.58)
Total 1043 66.7 522 33.4
* CWP5 chronic widespread pain; CPG5Chronic Pain Grade; OR5 odds ratio; 95% CI595% confidence interval.
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to those who never drunk regularly was 0.30 (95% CI
0.16–0.57).
Is reported alcohol consumption related to the likelihood
of having CWP? Among persons who responded to the
survey and reported never having drunk alcohol regularly,
the prevalence of CWP was 19.8% (Table 3). The preva-
lence of CWP decreased with increasing alcohol consump-
tion such that among persons who reported 11–20 units/
week or 21–35 units/week the prevalence of CWP was
13.1%, a large and significant decrease compared to never
regular drinkers, after adjustment for confounding factors
(adjusted OR 0.75 [95% CI 0.64–0.88] and adjusted OR 0.76
[95% CI 0.61–0.94], respectively). Persons who reported
drinking more than 35 units/week of alcohol had a preva-
lence similar to those who never drank alcohol regularly
(20.2%; adjusted OR 0.90 [95% CI 0.64–1.27]). There was
no statistically significant difference in the relationship
between alcohol consumption and CWP prevalence in men
and women, as assessed by an interaction term in the logis-
tic regression model; however, the lowest prevalence in
women was among those drinking 11–20 units/week (prev-
alence 14.8% versus 21.0% among never regular drinkers;
prevalence adjusted OR 0.76 [95% CI 0.61–0.95]), while in
men the lowest prevalence was among those drinking
21–25 units/week (prevalence 11.8% versus 16.7% among
never regular drinkers; prevalence adjusted OR 0.68 [95%
CI 0.51–0.91]). The same relationships were observed
between alcohol consumption and prevalence of CWP in
those with Carstairs Index scores available (Table 4). After
additional adjustment for deprivation, the ORs for report-
ing CWP in the groups drinking 11–20 units/week and
21–35 units/week compared to those who had never drunk
regularly were, respectively, 0.68 (95% CI 0.56–0.82) and
0.72 (95% CI 0.56–0.93).
DISCUSSION
This large population-based study has found that persons
with CWP are less likely to report their symptoms as dis-
abling if they also report regularly consuming alcohol, con-
firming a previous report in a smaller clinic study of patients
with fibromyalgia. Disability decreases with increasing re-
ported alcohol consumption, but at the very highest levels of
alcohol consumption (.35 units/week) disability is similar
to those who have never regularly consumed alcohol. We
also report for the first time that level of alcohol consump-
tion is also related to the likelihood of reporting CWP. Preva-
lence is highest in those who have never regularly drunk
alcohol or those reporting very high consumption (.35
units/week). Among other drinkers the likelihood of report-
ing CWP decreases with increasing consumption.
There are a number of methodologic issues to consider
in interpreting the results from this analysis. First, it is
well known that there is bias in the self-reporting of alco-
hol consumption in surveys (16). Respondents are likely
to have underestimated their alcohol consumption; the
Table 3. The relationship between reported alcohol consumption and CWP*
Reported units of
alcohol per week, no.
CWP, no CWP, yes
Crude
OR (95% CI)
Adjusted
OR (95% CI)No. % No. %
Never drunk regularly 3,039 80.2 752 19.8 1.00 1.00
0–5 3,225 83.6 634 16.4 0.79 (0.71–0.89) 0.89 (0.79–1.01)
6–10 2,247 84.7 405 15.3 0.73 (0.64–0.83) 0.88 (0.76–1.01)
11–20 1,811 86.9 274 13.1 0.61 (0.53–0.71) 0.75 (0.64–0.88)
21–35 807 86.9 122 13.1 0.61 (0.50–0.75) 0.76 (0.61–0.94)
.35 206 79.8 52 20.2 1.02 (0.74–1.40) 0.90 (0.64–1.27)
Total 11,335 83.5 2,239 16.5
* CWP5 chronic widespread pain; OR5odds ratio; 95% CI5 95% confidence interval.
Table 4. The relationship between reported alcohol consumption and CWP among those with Carstairs
Index scores available*
Reported units of
alcohol per
week, no.
CWP, no CWP, yes
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Adjusted for
deprivation
OR (95% CI)No. % No. %
Never drunk regularly 1,772 77.2 522 22.8 1.00 1.00 1.00
0–5 2,107 81.0 495 19.0 0.80 (0.69–0.92) 0.90 (0.78–1.04) 0.91 (0.79–1.05)
6–10 1,452 81.9 320 18.1 0.75 (0.64–0.87) 0.90 (0.76–1.06) 0.91 (0.78–1.08)
11–20 1,262 86.0 205 14.0 0.55 (0.46–0.66) 0.67 (0.55–0.80) 0.68 (0.56–0.82)
21–35 574 85.5 97 14.5 0.58 (0.45–0.73) 0.70 (0.55–0.91) 0.72 (0.56–0.93)
.35 136 76.8 41 23.2 1.02 (0.71–1.47) 0.86 (0.58–1.29) 0.87 (0.58–1.30)
Total 7,303 81.3 1,680 18.7
* CWP5 chronic widespread pain; OR5odds ratio; 95% CI5 95% confidence interval.
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effect of this underreporting, provided it is nondifferential
between persons with and without CWP, is that it would
cause us to underestimate an effect since, for example,
persons with high consumption were erroneously classi-
fied as drinking lower amounts of alcohol. Comparison
with national UK surveys of alcohol consumption is prob-
lematic since these have generally tried to estimate the
amount of alcohol drunk over a defined time in units,
whereas we asked subjects to classify themselves into
ranges of average alcohol consumption. However, since
the maximum recommended alcohol consumption for
men in the UK is 21 units/week (.14 units/week for
women), surveys generally report the percentage of men
exceeding this amount, and we can compare this with the
percentage in the current study reporting 21–35 and .35
units/week. The 2008 General Lifestyle Survey in the UK,
which involved 16,407 persons completing a question-
naire (74% participation rate), reported that 16.7% of men
drank more than 21 units/week (17), which compares
with 16.6% of men reporting alcohol consumption in the
top 2 categories of the current study. For women, 8.4%
reported consuming more than 14 units/week, which com-
pares with 13.9% reporting more than 10 units/week, and
2.8% reporting more than 20 units/week in the current
study. It therefore suggests that our reported levels of alco-
hol consumption in the current study are consistent with
national surveys in the UK. Second, the study was not
designed with the intention of addressing the current
hypotheses, and therefore we do not have all the data that
we would have wished for, particularly with respect to
potential confounding factors. Ideally we would have had
lifestyle factors (e.g., exercise) and individual characteris-
tics (e.g., depression), which are known to be markers of
CWP onset and related to alcohol consumption. Neverthe-
less, the groups that have been shown to be at low risk of
reporting CWP in this analysis (i.e., those with moderate-
high alcohol consumption) are those that are likely to
have lifestyle factors and individual characteristics (e.g.,
low mood, low levels of exercise) that would have put
them at high risk of onset. Therefore, it is not evident
whether the ability to adjust for such factors would have
attenuated or increased the associations demonstrated.
However, it was of note in this study, that after adjustment
for levels of deprivation (using the Carstairs Index) the
observed associations between alcohol consumption and
CWP and disability were largely unchanged.
We are only aware of a single study that has specifically
focused on the topic of fibromyalgia (that has CWP as its
characteristic feature) and alcohol consumption (11). We
have confirmed their results, studying CWP, that alcohol
consumption is associated with reduced disability from
fibromyalgia. Adding weight to the confirmation is the fact
that while the results were similar, the studies were con-
ducted in different countries (US versus UK), used differ-
ent sampling frames (fibromyalgia treatment program
versus population study), defined the outcome differently
(CWP versus fibromyalgia), and collected information on
alcohol consumption in different ways. Further, we have
additionally found that level of alcohol consumption is
also related to the likelihood of reporting CWP and not
just its severity. The current study is also considerably
larger, including more than 13,000 participants, more
than 2,000 of whom had CWP. The authors of the previous
study postulated a number of mechanisms linking alcohol
consumption with reduced disability, including that the
effects were mediated through g-aminobutyric acid
(GABA) production. Ethanol enhances GABA release in
the multiple brain regions (18) and, although they noted
that a recent study had shown decreased levels of GABA
in the brains of persons with fibromyalgia, this was only
observed in a single area, i.e., the anterior insula, while no
differences were found in the posterior insula, occipital
cortex, or anterior cingulate (19).
Aside from consideration of the possible mechanisms
whereby an association is observed, we think it is impor-
tant to evaluate to what extent a causal mechanism is
likely. Hill (20), in proposing his factors to consider
whether an association was causal or not, identified one
necessary criterion: temporality. The postulated risk factor
must precede the onset of disease (or symptoms). From
the available evidence of the 2 studies, it is not possible to
determine that this criterion is met. Both were cross-
sectional studies and could be observing the consequen-
ces of having CWP of a particular severity. For example, in
our study it may be that persons who have less disabling
symptoms have few restrictions on their daily activities
(including social activities) and are able to more fully
engage in pastimes that give rise to opportunities for social
consumption of alcohol. That may be true also for the
comparison of persons with and without CWP. However,
in our current study we have a category of “never having
regularly consumed alcohol,” and persons in this category
have a high prevalence of CWP and (if they have CWP)
high levels of disability. Provided that persons are truthfully
answering the questionnaire, their alcohol consumption
cannot have changed after the development of fibromyalgia
and does suggest that persons who have never consumed
alcohol have a high risk of symptoms/disabling symptoms.
In terms of other factors proposed by Hill, only strength
(i.e., the observed associations are large) and biologic gradi-
ent (i.e., risk appears to be related to dose) are definitely sat-
isfied. In terms of specificity (i.e., is the relationship only
observed with CWP/fibromyalgia?), it is of note that a rela-
tionship between alcohol consumption and health has been
observed for both general health and specific health condi-
tions (21). In a seminal prospective study of approximately
half a million US adults followed from 1982–91, Thun et al
(22) reported mortality rates from cardiovascular disease to
be significantly lower among men (relative risk [RR] 0.7,
95% CI 0.7–0.8) and women (RR 0.6, 95% CI 0.6–0.7)
reporting at least 1 drink daily (i.e., at least 7 units/week)
than among nondrinkers, with little relation to the level of
consumption. Overall mortality rates were lowest among
those consuming 1 drink per day, although mortality rates
increased among heavy drinkers. A so-called J-shaped
pattern of alcohol consumption and overall mortality has
been reported in other major studies (23,24). Specifically,
alcohol consumption has also been related to increased
mood, quality of life (25), and physical health (26). There-
fore, any effect of alcohol consumption on pain is not spe-
cific, and an alternative mechanism to a direct effect is that
alcohol has positive effects on general health, which influ-
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ences the reporting of pain. Indeed, general health status
has been found to be a strong predictor of pain onset in epi-
demiologic studies (27,28). Alternatively, alcohol may have
no positive effects on health at all either directly or indi-
rectly, and drinking within limits that are regarded in soci-
ety as normal may simply be a marker or indicator for those
with healthier lifestyles and beneficial levels of certain risk
factors (21).
In summary, this study has demonstrated associations
between alcohol consumption and likelihood of reporting
CWP and related disability. However, the available evidence
from 2 studies does not allow us to conclude that the associa-
tion is causal. It should not be interpreted that alcohol has a
therapeutic benefit, and we further note that, in these study
populations, a significant proportion of persons already
report consuming more than the recommended limit. The
magnitude of the associations (which are as strong as any
other identified associated factor with CWP) does mean that
further investigation and specific studies to examine this
potential relationship are warranted. If such an association
were true, it is unlikely to be directly beneficial to manage-
ment; it may, however, provide clues to the mechanisms of
development and outcome for CWP and fibromyalgia.
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APPENDIX A: MUSICIAN STUDY INVESTIGATORS
Investigators on the MUSICIAN study were as follows: Gordon
J. Prescott, Paul McNamee, Philip C. Hannaford (University of
Aberdeen); John McBeth, Karina Lovell, Phil Keeley, Deborah P.
M. Symmons (University of Manchester); Steve Woby (Penine
Acute NHS Trust). John Norrie was originally an investigator of
the MUSICIAN study while Director of the Centre for Health
Care Randomised Trials at the University of Aberdeen.
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